XML 155 R106.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Payments - Additional Information (Details)
€ / shares in Units, $ / shares in Units, $ in Billions
 1 Months Ended 12 Months Ended
Feb. 13, 2020
€ / shares
Feb. 13, 2020
$ / shares
Dec. 01, 2019
€ / shares
Oct. 10, 2019
€ / shares
Nov. 15, 2018
€ / shares
Dec. 31, 2020
EUR (€)
Sep. 30, 2019
€ / shares
Sep. 30, 2019
USD ($)
shares
$ / shares
May 31, 2019
May 31, 2019
€ / shares
Apr. 03, 2019
€ / shares
Apr. 03, 2019
Dec. 31, 2020
EUR (€)
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
EUR (€)
shares
Dec. 31, 2018
EUR (€)
2020 Restricted Stock Unit Plan                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses           € 0                    
Employee Equity Plan                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         € 1,015,000      
Option rights vesting term                         The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2. The BioNTech Employee 2020 Equity Plan share-based payment transaction for employees based in Europe includes two programs, LTI and LTI-plus. The LTI program will be offered to all employees. The LTI-plus program intends to compensate employees who did not participate in the ESOP. Under both programs, RSUs will be offered to employees based in Europe. Both programs are classified as equity-settled because BioNTech has the ability to determine the method of settlement. The LTI will vest annually in equal installments after four years commencing on December 15, 2020. The LTI-plus will vest annually in equal installments after two years commencing on December 15, 2020. Moreover, the LTI-plus contains a non-vesting condition concerning 50% of the granted RSUs. These units will be awarded to the participant after the FDA fully approves BNT162b2.    
Employee Equity Plan | Research and Development Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         € 681,000      
Employee Equity Plan | General And Administrative Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         147,000      
LTI Program                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Option rights vesting period           4 years                    
LTI-plus Program                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Option rights vesting period           2 years                    
Percentage of non-vesting rate           50.00%                    
Management Board Grant                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         2,760,000      
Other financial liabilities           € 700,000             € 700,000      
Percentage of exercise price increase                         7.00% 7.00%    
Threshold amount of dividend by number of shares outstanding immediately following initial public offering | $                           $ 8.5    
Percentage of target share price applicable for prior twelve month period                         107.00% 107.00%    
Option rights expiration period                         10 years 10 years    
Exercise price | (per share) € 28.32 $ 30.78                            
Options allocated and expected to be allocated, weighted-average expected life                         4 years 7 months 17 days 4 years 7 months 17 days    
Granted, share options | shares                         248,096 248,096    
Management Board Grant | Prof. Ugur Sahin, M.D.                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Grant of options, base value                         € 750,000      
Management Board Grant | Sean Marett                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Grant of options, base value                         300,000      
Management Board Grant | Dr. Sierk Poetting                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Grant of options, base value                         300,000      
Management Board Grant | Dr. Ozlem Tureci                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Grant of options, base value                         300,000      
Management Board Grant | Ryan Richardson                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Grant of options, base value                         260,000      
Increase (decrease) in grant of options, base value, for the year 2022                         280,000      
Management Board Grant | Research and Development Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         1,514,000      
Share-based payment expenses                         300,000      
Management Board Grant | General And Administrative Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         1,246,000      
Share-based payment expenses                         € 400,000      
Management Board Grant | Maximum                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Percentage of ADS to ordinary shares                         50.00% 50.00%    
Chief Executive Officer Grant                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Exercise price | € / shares       € 13.60                        
Granted, share options | shares                         0 0    
Forfeited, share options | shares                         0 0    
Options outstanding, weighted-average expected life                         4 years 1 month 13 days 4 years 1 month 13 days    
Chief Executive Officer Grant | Ordinary Shares                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Option rights vesting term                         The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder. The option vests annually in equal installments after four years commencing on the first anniversary of the initial public offering and will be exercisable four years after the initial public offering. The option is subject to the terms, conditions, definitions and provisions of the ESOP and the applicable option agreement thereunder.    
Option rights vesting period               4 years                
Percentage of exercise price increase               7.00%                
Threshold amount of dividend by number of shares outstanding immediately following initial public offering | $               $ 8.5                
Percentage of target share price applicable for prior twelve month period               107.00%                
Option to purchase ordinary shares | shares               4,374,963                
Exercise price in translation for IPO | (per share)             € 13.60 $ 15.00                
Chief Executive Officer Grant | Research and Development Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         € 11,300,000   € 3,200,000  
Chief Executive Officer Grant | Maximum | Ordinary Shares                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Option rights exercisable period               10 years                
Employee Stock Ownership Plan                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         € 17,075,000   € 27,028,000 € 7,641,000
Option rights vesting term                         The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation. The Option Rights vest over four years and can only be exercised if the company has executed a public offering in the United States (IPO) and when the Threshold Amount is met. Threshold Amount means the exercise price provided that such price increases by eight percentage points on the first and then each subsequent anniversary of the Allocation Date (September 26, 2018). The Option Rights can be exercised at the latest eight years after the Allocation Date. If they have not been exercised by that date, they will be forfeited without compensation.    
Option rights vesting period         4 years                      
Percentage of exercise price increase     8.00%   8.00%       8.00%     8.00%        
Exercise price | € / shares     € 15.82   € 10.14         € 15.39 € 15.03          
Option rights exercisable period         8 years                      
Granted, share options | shares                             14,511  
Forfeited, share options | shares                         9,491 9,491 17,237  
Options outstanding, weighted-average expected life                         3 years 8 months 23 days 3 years 8 months 23 days    
Employee Stock Ownership Plan | Research and Development Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         € 11,120,000   € 20,016,000 6,786,000
Employee Stock Ownership Plan | General And Administrative Expenses                                
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]                                
Share-based payment expenses                         € 4,975,000   € 6,008,000 € 728,000